| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Advances in Brief |
Department of Epidemiology and Preventive Medicine, University of Maryland, Baltimore, Maryland 21201 [A. P. C.]; Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, Maryland 20892 [A. P. C., K. A. M., J. F. F., A. W. H.]; Shanghai Cancer Institute, Shanghai 200032, China [Y-T. G., J. D.]; Cancer Prevention Research Unit, Jewish General Hospital and Department of Oncology, McGill University, Montreal, Ontario H3T 1E2, Canada [M. P.]; and Armed Forces Institute of Pathology, Washington, DC 20306 [I. A. S, F. K. M.]
Operating through the vitamin D receptor (VDR), vitamin D inhibits prostate cancer growth and increases insulin-like growth factor binding protein (IGFBP) expression, suggesting that the vitamin D and insulin-like growth factor (IGF) regulatory systems may operate together to affect prostate cancer. Among 191 newly diagnosed prostate cancer cases and 304 randomly selected population controls in Shanghai, China, we found no significant association between the BsmI or FokI VDR gene polymorphisms and prostate cancer risk. However, we found that among men with the ff FokI genotype, those in the highest tertile of plasma IGFBP-3 had a decreased risk versus those in the lowest tertile (odds ratio, 0.14; 95% confidence interval, 0.040.56; Ptrend < 0.01), whereas among men with the FF and Ff genotypes, IGFBP-3 was not associated with risk. Similarly, IGFBP-1 was inversely associated with prostate cancer risk only among men with the ff FokI genotype (odds ratio, 0.25; 95% confidence interval, 0.070.85; Ptrend = 0.02). No such FokI genotype-specific effects were observed for IGF-I or IGF-II. Our findings in a low-risk population suggest that the IGF and vitamin D regulatory systems may interact to affect prostate cancer risk. Larger studies are needed to confirm these findings and clarify the underlying mechanisms.
This article has been cited by other articles:
![]() |
L. Chen, G. Davey Smith, D. M. Evans, A. Cox, D. A. Lawlor, J. Donovan, W. Yuan, I. N. M. Day, R. M. Martin, A. Lane, et al. Genetic Variants in the Vitamin D Receptor Are Associated with Advanced Prostate Cancer at Diagnosis: Findings from the Prostate Testing for Cancer and Treatment Study and a Systematic Review Cancer Epidemiol. Biomarkers Prev., November 1, 2009; 18(11): 2874 - 2881. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. KOSTNER, N. DENZER, C. S.L. MULLER, R. KLEIN, W. TILGEN, and J. REICHRATH The Relevance of Vitamin D Receptor (VDR) Gene Polymorphisms for Cancer: A Review of the Literature Anticancer Res, September 1, 2009; 29(9): 3511 - 3536. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. H. Onen, A. Ekmekci, M. Eroglu, E. Konac, S. Yesil, and H. Biri Association of Genetic Polymorphisms in Vitamin D Receptor Gene and Susceptibility to Sporadic Prostate Cancer Experimental Biology and Medicine, December 1, 2008; 233(12): 1608 - 1614. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. E. Mullin and A. Dobs Vitamin D and Its Role in Cancer and Immunity: A Prescription for Sunlight Nutr Clin Pract, June 1, 2007; 22(3): 305 - 322. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Diorio, S. Berube, C. Byrne, B. Masse, N. Hebert-Croteau, M. Yaffe, G. Cote, M. Pollak, and J. Brisson Influence of Insulin-like Growth Factors on the Strength of the Relation of Vitamin D and Calcium Intakes to Mammographic Breast Density Cancer Res., January 1, 2006; 66(1): 588 - 597. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. M. John, G. G. Schwartz, J. Koo, D. Van Den Berg, and S. A. Ingles Sun Exposure, Vitamin D Receptor Gene Polymorphisms, and Risk of Advanced Prostate Cancer Cancer Res., June 15, 2005; 65(12): 5470 - 5479. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. M. Schildkraut, W. Demark-Wahnefried, R. M. Wenham, J. Grubber, A. S. Jeffreys, S. C. Grambow, J. R. Marks, P. G. Moorman, C. Hoyo, S. Ali, et al. IGF1 (CA)19 Repeat and IGFBP3 -202 A/C Genotypes and the Risk of Prostate Cancer in Black and White Men Cancer Epidemiol. Biomarkers Prev., February 1, 2005; 14(2): 403 - 408. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. L. Slattery, W. Samowitz, K. Curtin, K. N. Ma, M. Hoffman, B. Caan, and S. Neuhausen Associations among IRS1, IRS2, IGF1, and IGFBP3 Genetic Polymorphisms and Colorectal Cancer Cancer Epidemiol. Biomarkers Prev., July 1, 2004; 13(7): 1206 - 1214. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Ntais, A. Polycarpou, and J. P. A. Ioannidis Vitamin D Receptor Gene Polymorphisms and Risk of Prostate Cancer: A Meta-analysis Cancer Epidemiol. Biomarkers Prev., December 1, 2003; 12(12): 1395 - 1402. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. K. Nam, W. W. Zhang, J. Trachtenberg, M. A. S. Jewett, M. Emami, D. Vesprini, W. Chu, M. Ho, J. Sweet, A. Evans, et al. Comprehensive Assessment of Candidate Genes and Serological Markers for the Detection of Prostate Cancer Cancer Epidemiol. Biomarkers Prev., December 1, 2003; 12(12): 1429 - 1437. [Abstract] [Full Text] [PDF] |
||||
![]() |
H.-L. Wong, A. Seow, K. Arakawa, H.-P. Lee, M. C. Yu, and S. A. Ingles Vitamin D receptor start codon polymorphism and colorectal cancer risk: effect modification by dietary calcium and fat in Singapore Chinese Carcinogenesis, June 1, 2003; 24(6): 1091 - 1095. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Xu, A. Shibata, J. E. McNeal, T. A. Stamey, D. Feldman, and D. M. Peehl Vitamin D Receptor Start Codon Polymorphism (FokI) and Prostate Cancer Progression Cancer Epidemiol. Biomarkers Prev., January 1, 2003; 12(1): 23 - 27. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |